Acetyltransferases and susceptibility to chemicals.

Arylamine chemicals inflict a number of toxicities including cancer. Metabolic activation (i.e., oxidation) is required in order to elicit the toxic actions. Acetylation is an important step in the metabolic activation and deactivation of arylamines. N-acetylation forms the amide derivative which is often nontoxic. However, O-acetylation of the N-hydroxyarylamine (following oxidation) yields an acetoxy arylamine derivative which breaks down spontaneously to a highly reactive arylnitrenium ion, the ultimate metabolite responsible for mutagenic and carcinogenic lesions. Human capacity to acetylate arylamine chemicals is subject to a genetic polymorphism. Individuals segregate into rapid, intermediate, or slow acetylator phenotypes by Mendelian inheritance regulated by a single gene encoding for a polymorphic acetyltransferase isozyme (NAT2). Individuals homozygous for mutant alleles are deficient in the polymorphic acetyltransferase and are slow acetylators. A second acetyltransferase isozyme (NAT1) is monomorphic and is not regulated by the acetylator genotype. Several human epidemiological studies suggest an association between slow acetylator phenotype and urinary bladder cancer. In contrast, a few studies suggest a relationship between rapid acetylator phenotype and colorectal cancer. The basis for this paradox may relate to the relative importance of N- versus O-acetylation in the etiology of these cancers. Conclusions drawn from human epidemiological data are often compromised by uncontrolled environmental and other genetic factors. Our laboratory recently completed construction of homozygous rapid, heterozygous intermediate, and homozygous slow acetylator congenic Syrian hamsters to be homologous in greater than 99.975% of their genomes. The availability of these acetylator congenic lines should eliminate genetic variability in virtually all aspects of arylamine carcinogenesis except at the acetylator gene locus. Ongoing studies in these congenic hamster lines should provide unequivocal information regarding the role of genetic acetylator phenotype in susceptibility to arylamine-related cancers.

[1]  D. Hein,et al.  Acetylator genotype-dependent expression of arylamine N-acetyltransferase and N-hydroxyarylamine O-acetyltransferase in Syrian inbred hamster intestine and colon. Identity with the hepatic acetylation polymorphism. , 1990, Drug metabolism and disposition: the biological fate of chemicals.

[2]  U. Meyer,et al.  Nucleotide sequence of rabbit NAT2 encoding polymorphic liver arylamine N-acetyltransferase (NAT). , 1990, Nucleic acids research.

[3]  R. Minchin,et al.  Distribution of acetyltransferase activities in the intestines of rapid and slow acetylator rabbits. , 1991, Carcinogenesis.

[4]  D. Hein,et al.  Acetylator genotype-dependent expression of arylamine N-acetyltransferase in human colon cytosol from non-cancer and colorectal cancer patients. , 1991, Cancer research.

[5]  P. K. Brady,et al.  Polymorphic expression of acetyl coenzyme A-dependent arylamine N-acetyltransferase and acetyl coenzyme A-dependent O-acetyltransferase-mediated activation of N-hydroxyarylamines by human bladder cytosol. , 1989, Cancer research.

[6]  W. Weber,et al.  Diverse point mutations in the human gene for polymorphic N-acetyltransferase. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[7]  U. Meyer,et al.  Nucleotide sequence of rabbit NAT1 encoding monomorphic arylamine N-acetyltransferase. , 1990, Nucleic acids research.

[8]  T. Rustan,et al.  Acetylator phenotype-dependent and -independent expression of arylamine N-acetyltransferase isozymes in rapid and slow acetylator inbred rat liver. , 1991, Drug metabolism and disposition: the biological fate of chemicals.

[9]  W. Weber,et al.  Biochemical investigation of the basis for the genetic N-acetylation polymorphism in the inbred hamster. , 1985, The Journal of pharmacology and experimental therapeutics.

[10]  D. Hein.  A New Model for Toxic Risk Assessments: Construction of Homozygous Rapid and Slow Acetylator Congenic Syrian Hamster Lines , 1991 .

[11]  W. Weber,et al.  Kinetics of acetyl CoA: arylamine N-acetyltransferase from rapid and slow acetylator human liver. , 1991, Drug Metabolism And Disposition.

[12]  W. Weber,et al.  Genetic control of acetyl coenzyme A-dependent arylamine N-acetyltransferase, hydrazine N-acetyltransferase, and N-hydroxy-arylamine O-acetyltransferase enzymes in C57BL/6J, A/J, AC57F1, and the rapid and slow acetylator A.B6 and B6.A congenic inbred mouse. , 1988, Drug metabolism and disposition: the biological fate of chemicals.

[13]  D. Grant,et al.  Molecular mechanism of slow acetylation of drugs and carcinogens in humans. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[14]  D. Hein.  Acetylator genotype and arylamine-induced carcinogenesis. , 1988, Biochimica et biophysica acta.

[15]  D. Grant,et al.  Monomorphic and polymorphic human arylamine N-acetyltransferases: a comparison of liver isozymes and expressed products of two cloned genes. , 1991, Molecular pharmacology.

[16]  T. Rustan,et al.  Polymorphic and monomorphic expression of arylamine carcinogen N-acetyltransferase isozymes in tumor target organ cytosols of Syrian hamsters congenic at the polymorphic acetyltransferase locus. , 1991, The Journal of pharmacology and experimental therapeutics.